295 related articles for article (PubMed ID: 11747684)
1. The role of serial bone mineral density testing for osteoporosis.
Crandall C
J Womens Health Gend Based Med; 2001 Nov; 10(9):887-95. PubMed ID: 11747684
[TBL] [Abstract][Full Text] [Related]
2. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
Cummings SR; Palermo L; Browner W; Marcus R; Wallace R; Pearson J; Blackwell T; Eckert S; Black D
JAMA; 2000 Mar; 283(10):1318-21. PubMed ID: 10714731
[TBL] [Abstract][Full Text] [Related]
3. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
[TBL] [Abstract][Full Text] [Related]
4. Initiation of osteoporosis treatment after bone mineral density testing.
Pressman A; Forsyth B; Ettinger B; Tosteson AN
Osteoporos Int; 2001; 12(5):337-42. PubMed ID: 11444079
[TBL] [Abstract][Full Text] [Related]
5. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment.
Adachi JD; Adami S; Kulkarni PM; Wong M; Stock JL
J Clin Densitom; 2005; 8(3):273-7. PubMed ID: 16055956
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
7. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
9. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.
Chapurlat RD; Palermo L; Ramsay P; Cummings SR
Osteoporos Int; 2005 Jul; 16(7):842-8. PubMed ID: 15580479
[TBL] [Abstract][Full Text] [Related]
10. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents.
Wimalawansa SJ
J Clin Densitom; 2000; 3(2):187-201. PubMed ID: 10871912
[TBL] [Abstract][Full Text] [Related]
12. The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal women with osteoporosis.
Hayashi T; Ina K; Maeda M; Nomura H
Nitric Oxide; 2011 May; 24(4):199-203. PubMed ID: 21513812
[TBL] [Abstract][Full Text] [Related]
13. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
[TBL] [Abstract][Full Text] [Related]
14. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
Greendale GA; Espeland M; Slone S; Marcus R; Barrett-Connor E;
Arch Intern Med; 2002 Mar; 162(6):665-72. PubMed ID: 11911720
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment of osteoporosis: a clinical review.
Crandall C
J Womens Health Gend Based Med; 2002 Apr; 11(3):211-24. PubMed ID: 11988132
[TBL] [Abstract][Full Text] [Related]
16. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
17. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
18. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
Greenspan SL; Resnick NM; Parker RA
JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324
[TBL] [Abstract][Full Text] [Related]
20. [Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Lems WF; Dijkmans BA
Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1941-5. PubMed ID: 11048556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]